01801 INNOVENT BIOWatchlist
INNOVENT BIO News
Cinda Biotech (01801) published the latest clinical results of anti-PD-1 monoclonal antibody in JAMA's main journal
On December 6, Cinda Biotech (01801) announced that it published the interim analysis results of the phase 3 clinical study ORIENT-16 on first-line treatment of adenocarcinoma at the gastric and gastroesophageal junction with cindilizumab injection combined with chemotherapy in the main journal of the “Journal of the American Medical Association” (JAMA).
Hong Kong Stock Concept Tracking | 100 billion dollars space! New players are pouring into the GLP-1 diet drug race into the country, and these companies have a layout (with concept stocks)
Following diet drug giants Novo Nordisk (NVO.US) and Lly.US (LL.US), another player is targeting the diet drug sector.
Cinda Biotech announced two clinical study data updates on IBI351 (KRAS G12C inhibitor) monotherapy for lung cancer and colorectal cancer at the 2023 ESMO Asia Conference
Rockville, USA, Suzhou, China, December 1, 2023/PRNewswire/ -- Cinda Biopharmaceutical Group (HKSE stock code: 01801), a biopharmaceutical company dedicated to the development, production and sale of innovative drugs in the fields of oncology, autoimmunity, metabolism, ophthalmology and other major diseases, announced two clinical study data updates on IBI351 (KRAS G12C inhibitor) monotherapy for lung cancer and colorectal cancer at the 2023 ESMO Asia Conference (ESMO Asia) of the European Society of Internal Medicine in Oncology (ESMO Asia).
Changes in Hong Kong stocks | Cinda Biotech (01801) rose nearly 4%; IBI351's new drug marketing application was officially accepted by the State Drug Administration and included in priority review
Cinda Biotech (01801) rose nearly 4%. As of press release, it was up 3.54% to HK$45.3, with a turnover of HK$361 million.
[Broker Focus] CITIC Construction Investment maintains Cinda Biotech's (01801) “buy” rating, and the company is expected to usher in a new round of growth in the future
According to the CITIC Construction Investment Research Report, Cinda Biotech (01801) has deployed a variety of excellent products on the oncology circuit, covering a wide range of patients. As ROS1 TKI and KRAS G12C TKI both submit listing applications, the company's oncology pipeline is expected to be strengthened and overall sales will experience further growth.
China's First NDA for a KRAS G12C Inhibitor: Innovent Announces the National Medical Products Administration of China Has Accepted and Granted Priority Review Designation to the New Drug Application for IBI351
ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commerciali
[Hong Kong Stock Connect] Cinda Biotech (01801): KRAS G12C inhibitor marketing application accepted by FDA
Jinwu Financial News | Cinda Biotech (01801) announced that the China National Drug Administration (“NMPA”) has officially accepted the new drug marketing license application (“NDA”) for IBI-351 (KRAS G12C inhibitor) and included it in the priority review process to treat patients with advanced non-small cell lung cancer (“NSCLC”) with a KRAS G12C mutation who have received at least one type of systematic treatment. IBI-351 is the first KRAS G12C inhibitor submitted to an NDA in China and included in priority review. It is expected to benefit KRAS G12C mutations as soon as possible
Innovent Biologics, Inc.'s (HKG:1801) Shift From Loss To Profit
Innovent Biologics, Inc. (HKG:1801) is possibly approaching a major achievement in its business, so we would like to shine some light on the company.
China Accepts Innovent Biologics' New Drug Application for Lung Cancer Treatment
The National Medical Products Administration of China has accepted Innovent Biologics' (HKG:1801) new drug application for Taletrectinib, a Wednesday filing by the pharmaceutical company said. The app
Cinda Biotech (01801): China Drug Administration accepts a new drug marketing application for the ROS1 inhibitor telletinib
Cinda Biotech (01801) issued an announcement that the China National Drug Administration (NMPA) has officially accepted the next one...
Diabetes Care publishes full results of Cinda Biotech's phase II clinical study of mastidotide (IBI362) in Chinese type 2 diabetes subjects
Rockwell, USA, and Suzhou, China, November 22, 2023/PRNewswire/ -- Cinda Biopharmaceutical Group (HKSE stock code: 01801), a biopharmaceutical company dedicated to the development, production and sale of innovative drugs in the fields of oncology, autoimmunity, metabolism, ophthalmology and other major diseases, announced: glucagon-like peptide-1 receptor (glucagon-like peptide-1 receptor, GLP-1R) /glucagon receptor (glucagon receptor, GCGR) Dual Agonist Masetol
China Approves Innovent's Drug for Chronic-Phase Myeloid Leukemia in Adults
China's medical products administrator approved Innovent Biologics' (HKG:1801) usage of olverembatinib for adult patients with chronic-phase chronic myeloid leukemia, a Friday filing said. The indicat
Hong Kong stock announcement Nuggets | MEGA bookings exceeded 10,000, and delivery volume reached a record high in the third quarter
On the profit side, the company's Q3 net profit was 2.81 billion yuan, an increase of 4.45 billion yuan over the same period in 2022, and has achieved four consecutive quarters of profit. The company delivered 105108 new energy vehicles in the third quarter, a year-on-year increase of 296.3%, a record high.
Selected Gelonghui Announcements (Hong Kong Stocks) | Ideal Auto: Ideal MEGA started on November 17, pre-orders have exceeded 10,000 vehicles within 2 hours
[Today's Focus] Ideal Automobile-W (02015.HK): Ideal MEGA started pre-orders on November 17 and has already surpassed 10,000 vehicles within 2 hours (02015.HK). It was announced that its family technology flagship MPV-Ideal MEGA was unveiled at the 21st Guangzhou International Auto Show (2023 Guangzhou Auto Show). At the 2023 Guangzhou Auto Show, the company gave a brief introduction to the outstanding performance of Ideal MEGA in terms of safety, pure electric technology, space, drivability and comfort, and design. Ideal MEGA is already in 2023
Guohai Securities: The weight reduction drug industry ushered in a period of achievements, breakthroughs, and explosions, focusing on related targets where research and development is progressing rapidly
With the GLP-1 target weight reduction drug trend led by Novo Nordisk and Lilly, the weight loss drug industry ushered in a period of breakthrough results.
Changes in Hong Kong stocks | Innovative drug concepts buck the market and rise, national health insurance negotiations officially begin, agencies say price cuts may be less than expected
The concept of innovative drugs bucked the market. As of press release, Hualing Pharmaceutical-B (02552) rose 12.28% to HK$1.92; Connoah-B (02162) rose 7.96% to HK$54.25; Genting Xinyao B (01952) rose 6.8% to HK$27.5; and Cinda Biotech (01801) rose 2.99% to HK$44.8.
Huaxin Securities: Optimistic about GLP-1RA's flexible growth in the field of multiple chronic diseases and the industry's “recommended” rating
We are optimistic about GLP-1RA's flexible growth in the fields of overweight/obesity, diabetes, and many future chronic diseases, and give the industry a “recommendation” rating.
Bank of China Fund Zheng Ning: Optimistic about the pharmaceutical industry's reversal, in-hospital product-side companies, especially innovative drugs, are worth paying attention to
Recently, Bank of China Fund Zheng Ning said in an in-depth interview that in the next rise in the pharmaceutical industry, the hospital's product-side companies, especially innovative drugs, are expected to take the lead.
Nomura Adjusts Innovent Biologics' Price Target to HK$54.51 From HK$45.73, Keeps at Buy
05:27 AM EST, 11/06/2023 (MT Newswires) -- Nomura Adjusts Innovent Biologics' Price Target to HK$54.51 From HK$45.73, Keeps at Buy Price (HKD): $48.40, Change: $+2.20, Percent Change: +4.76%
Nomura: Yuxinda Biotech's “buy” rating target price rises to HK$54.51
According to a research report released by Nomura, the target price of Cinda Biotech (01801) was raised by 19%, from HK$45.73 to HK$54.51, benefiting from the positive prospects of the drug GLP-1R/GCCR candidate, and the “buy” rating.